As geopolitical tensions and economic uncertainties continue to shape the Middle East market, investors are closely monitoring developments such as the Trump-Xi meeting for potential impacts on regional stability and energy prices. Despite recent dips in key Gulf indices, these conditions may present opportunities for identifying promising stocks that demonstrate resilience and growth potential amidst volatility.

Top 10 Undiscovered Gems With Strong Fundamentals In The Middle East

Name	Debt To Equity	Revenue Growth	Earnings Growth	Health Rating
Al Wathba National Insurance Company PJSC	10.35%	8.65%	-7.40%	★★★★★★
C. Mer Industries	70.13%	13.00%	68.68%	★★★★★★
Saudi Azm for Communication and Information Technology	14.04%	16.38%	23.83%	★★★★★★
MOBI Industry	7.46%	5.89%	17.98%	★★★★★★
Nofoth Food Products	NA	15.50%	18.29%	★★★★★★
Baazeem Trading	9.26%	-0.72%	-0.40%	★★★★★☆
Kirac Galvaniz Telekominikasyon Metal Makine Insaat Elektrik Sanayi ve Ticaret Anonim Sirketi	21.92%	19.33%	42.01%	★★★★★☆
Etihad GO Telecom	0.74%	38.31%	54.97%	★★★★★☆
Saudi Chemical Holding	47.39%	17.85%	39.66%	★★★★★☆
Zahrat Al Waha For Trading	56.06%	-0.88%	-37.72%	★★★★☆☆

We'll examine a selection from our screener results.

Saudi Manpower Solutions (SASE:1834)

Simply Wall St Value Rating: ★★★★★★

Overview: Saudi Manpower Solutions Company offers recruitment, manpower, and logistics services to workers, government, and private sectors in Saudi Arabia with a market capitalization of SAR 2.34 billion.

Operations: The company generates revenue primarily through recruitment, manpower, and logistics services. Its financial performance is highlighted by a net profit margin of 10.5%, reflecting its efficiency in converting revenue into actual profit.

Saudi Manpower Solutions, a nimble player in the Middle East's staffing industry, has shown robust growth with earnings climbing 23.4% over the past year, outpacing the sector's 11%. The company is debt-free for five years and boasts high-quality earnings. Recent figures reveal that its first-quarter sales reached SAR 557 million, up from SAR 498 million last year, while net income rose to SAR 48.58 million from SAR 40.49 million. With a dividend payout of SAR 60 million scheduled for April, it seems poised for continued investor interest given its solid performance trajectory and strategic financial management.

National Company for Glass Industries (SASE:2150)

Simply Wall St Value Rating: ★★★★★★

Overview: The National Company for Glass Industries specializes in the production and sale of both returnable and non-returnable glass bottles as well as float glass, with a market capitalization of SAR1.25 billion.

Operations: The company generates revenue through the sale of returnable and non-returnable glass bottles and float glass. It has a market capitalization of SAR1.25 billion.

National Company for Glass Industries, a nimble player in the Middle East's glass manufacturing sector, has shown promising financial metrics. Its debt to equity ratio impressively decreased from 12.8% to 3.6% over five years, indicating prudent financial management. The company boasts a net debt to equity ratio of 1.7%, which is considered satisfactory and reflects sound leverage control. Recent earnings reports highlight robust growth with net income reaching SAR 32.71 million for Q1 2026, compared to SAR 18.1 million the previous year, alongside basic earnings per share rising from SAR 0.55 to SAR 0.99 during the same period, showcasing its capacity for profit generation amidst industry challenges.

Middle East Pharmaceutical Industries (SASE:4016)

Simply Wall St Value Rating: ★★★★★★

Overview: Middle East Pharmaceutical Industries Company focuses on the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations both in Saudi Arabia and internationally, with a market cap of SAR2.07 billion.

Operations: The company generates revenue through the sale of generic medicines and pharmaceutical preparations. It operates in both domestic and international markets, with a market cap of SAR2.07 billion.

Middle East Pharma, a nimble player in the industry, has shown impressive strides with its recent sales hitting SAR 130.13 million for Q1 2026, up from SAR 97.36 million the previous year. Net income rose to SAR 26.9 million from SAR 19.4 million, reflecting robust growth that outpaces industry norms at a rate of 16.3%. The company’s debt situation appears manageable with a net debt to equity ratio of just 15.4%, and interest payments are comfortably covered by EBIT at over thirty-three times coverage, suggesting sound financial health and potential for continued performance improvements in this dynamic sector.

Seize The Opportunity

• Get an in-depth perspective on all 223 Middle Eastern Undiscovered Gems With Strong Fundamentals by using our screener here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.